FDA Takes New Steps to Increase the Safety of Laparoscopic Power Morcellators when used in Gynecologic Surgeries

February 25, 2020 FDA

FDA takes several steps to make the use of laparoscopic power morcellators safer in gynecologic surgeries: grants marketing authorization for updated labeling, releases draft guidance and issues a Safety Communication.

Previous Article
FDA Approves First Generic of Daraprim
FDA Approves First Generic of Daraprim

FDA has approved an application for first generic of Daraprim (pyrimethamine).

Next Article
FDA Authorizes Marketing of the First Genetic Test to Aid in the Diagnosis of Fragile X Syndrome
FDA Authorizes Marketing of the First Genetic Test to Aid in the Diagnosis of Fragile X Syndrome

Today, FDA authorized marketing of the first test to detect a genetic condition known as Fragile X Syndrome...